Skip to main content
. 2022 Apr 12;25(5):104241. doi: 10.1016/j.isci.2022.104241

Figure 7.

Figure 7

Tryptamine promotes mTOR activation in vitro and glycolysis in vivo in TC CD4+ T cells

(A–C) p4EBP1 and pS6 expression (MFI) in Tn (A), Tem (B), and Treg (C) cells gated from TC and B6 total CD4+ T cells incubated for 24 h with and without tryptamine.

(D) Frequency of IFNγ-producing CD4+ T cells after 96 h activation with and without kynurenine.

(E–H) Glycolysis stress assay on total CD4+ T cells from vehicle or tryptamine-treated TC mice.

(E) Complete assay with indications of the glucose, oligomycin, and 2DG injections.

(F) Basal ECAR before glucose injection. (F) Glycolysis: mean 3 values after glucose minus before glucose injections.

(H) Ratio of basal OCR and ECAR. (A–D) Graphs show paired t-tests between treated and control cells for each strain and subset (n = 5 for A-C, n = 8 for D).

(F–H) t tests (n = 9–12 from 2 cohorts). Graphs show individual mice with mean ± SEM ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001.